The altered lung microbiome dynamics in patients with moderate and severe COPD compared to the healthy group in the Indian population

Background: Microbial culture-independent sequencing techniques have advanced our understanding of host-microbiome interactions in health and disease. The purpose of this study was to explore the dysbiosis of airway microbiota in patients with moderate or severe chronic obstructive pulmonary disease (COPD) and compare them with healthy controls. Methods: The COPD patients were investigated for disease severity based on airflow limitations and divided into moderate (50%≤FEV1<80% predicted) and severe groups (FEV1<50% predicted). Spontaneous sputum samples were collected and, the V3-V4 regions of the 16S rRNA coding gene were sequenced to examine the microbiome profile of COPD and healthy participants.  Results: A total of 45 sputum samples were collected from 17 severe COPD, 12 moderate COPD cases, and 16 healthy volunteers. The bacterial alpha diversity (Shannon and Simpson’s index) significantly decreased in the moderate and severe COPD groups, compared to healthy samples. A significantly higher proportion of Firmicutes and Actinobacteria were present in moderate COPD, and Proteobacteria numbers were comparatively increased in severe COPD. In healthy samples, Bacteroidetes and Fusobacteria were more abundant in comparison to both the COPD groups. Among the most commonly detected 20 bacterial genera, Streptococcus was predominant among the COPD sputum samples, whereas Prevotella was the top genus in healthy controls. Linear discriminant analysis (LDA>2) revealed that marker genera like Streptococcus and Rothia were abundant in moderate COPD. For severe COPD, the genera Pseudomonas and Leptotrichia were most prevalent, whereas Fusobacterium and Prevotella were dominant in the healthy group. Conclusions: Our findings suggest a significant dysbiosis of the respiratory microbiome in COPD patients. The decreased microbial diversity may influence the host immune response and provide microbiological biomarkers for the diagnosis and monitoring of COPD.

[1]  Wei Li,et al.  Analysis of sputum microbial metagenome in COPD based on exacerbation frequency and lung function: a case control study , 2022, Respiratory Research.

[2]  L. Segal,et al.  The dynamic lung microbiome in health and disease , 2022, Nature Reviews Microbiology.

[3]  G. Collins,et al.  Burden of chronic obstructive pulmonary disease and its attributable risk factors in 204 countries and territories, 1990-2019: results from the Global Burden of Disease Study 2019 , 2022, BMJ.

[4]  Sarah E Clark,et al.  Airway Prevotella promote TLR2-dependent neutrophil activation and rapid clearance of Streptococcus pneumoniae from the lung , 2022, Nature Communications.

[5]  Jianchao Wei,et al.  Targeting the Pulmonary Microbiota to Fight against Respiratory Diseases , 2022, Cells.

[6]  Hongbing Zhang,et al.  Characteristics of the sputum microbiome in COPD exacerbations and correlations between clinical indices , 2022, Journal of translational medicine.

[7]  P. Parás-Bravo,et al.  Cost analysis of chronic obstructive pulmonary disease (COPD): a systematic review , 2021, Health Economics Review.

[8]  S. Heath,et al.  Lung microbiome composition and bronchial epithelial gene expression in patients with COPD versus healthy individuals: a bacterial 16S rRNA gene sequencing and host transcriptomic analysis. , 2021, The Lancet. Microbe.

[9]  Chi-Ching Lee,et al.  Association of exacerbation phenotype with the sputum microbiome in chronic obstructive pulmonary disease patients during the clinically stable state , 2021, Journal of Translational Medicine.

[10]  A. Ismaila,et al.  Economic Burden of Chronic Obstructive Pulmonary Disease (COPD): A Systematic Literature Review , 2020, International journal of chronic obstructive pulmonary disease.

[11]  James R. Brown,et al.  Airway host-microbiome interactions in chronic obstructive pulmonary disease , 2019, Respiratory Research.

[12]  Highlights from this issue , 2018, Thorax.

[13]  C. Reilly,et al.  The lung tissue microbiota of mild and moderate chronic obstructive pulmonary disease , 2017, Microbiome.

[14]  K. Hao,et al.  Role of the Lung Microbiome in the Pathogenesis of Chronic Obstructive Pulmonary Disease , 2017, Chinese medical journal.

[15]  James R. Brown,et al.  Lung microbiome dynamics in COPD exacerbations , 2016, European Respiratory Journal.

[16]  T. Kiljander,et al.  Annual costs of chronic obstructive pulmonary disease in Finland during 1996–2006 and a prediction model for 2007–2030 , 2015, npj Primary Care Respiratory Medicine.

[17]  V. Pérez-Brocal,et al.  Severity-Related Changes of Bronchial Microbiome in Chronic Obstructive Pulmonary Disease , 2014, Journal of Clinical Microbiology.

[18]  Gert Folkerts,et al.  Bifidobacterium breve and Lactobacillus rhamnosus treatment is as effective as budesonide at reducing inflammation in a murine model for chronic asthma , 2014, Respiratory Research.

[19]  Pelin Yilmaz,et al.  The SILVA ribosomal RNA gene database project: improved data processing and web-based tools , 2012, Nucleic Acids Res..

[20]  Joel Cooper,et al.  The lung tissue microbiome in chronic obstructive pulmonary disease. , 2012, American journal of respiratory and critical care medicine.

[21]  J. Curtis,et al.  Analysis of the Lung Microbiome in the “Healthy” Smoker and in COPD , 2011, PloS one.

[22]  Martin Hartmann,et al.  Introducing mothur: Open-Source, Platform-Independent, Community-Supported Software for Describing and Comparing Microbial Communities , 2009, Applied and Environmental Microbiology.

[23]  F. Martinez,et al.  Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. , 2007, American journal of respiratory and critical care medicine.

[24]  C. Mathers,et al.  Projections of Global Mortality and Burden of Disease from 2002 to 2030 , 2006, PLoS medicine.